ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice (Q40736250)

26175148

23 September 2017

title

ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice (English)

1 reference

23 September 2017

Angela W Corona

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

Nathan Kodoma

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

Brad T Casali

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

Gary E Landreth

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

language of work or name

1 reference

15 July 2015

1 reference

26175148

Journal of Neuroimmune Pharmacology

23 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

page(s)

61-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

describes a project that uses

14 May 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6558963/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

HDL and cognition in neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Co-expression of multiple transgenes in mouse CNS: a comparison of strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

ApoE promotes the proteolytic degradation of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

ABCA1 influences neuroinflammation and neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Regulation of microglia activation and deactivation by nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Nuclear receptors in neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Apolipoprotein E in Alzheimer's disease and other neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Evidence for impaired amyloid β clearance in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9627-8

Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26175148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26175148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11481-015-9627-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json

14 May 2020

26175148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6558963&resulttype=core&format=json